Solara Active Pharma Sciences PAT slides to Rs 29.71 cr in Q2FY22

Solara Active Pharma Sciences has reported consolidated financial results for the period ended September 30, 2021.

Solara Active Pharma Science clocks net profit of Rs 50.13 crore in Q1FY22

Aditya Puri former MD of HDFC bank joins Solara board as chairman

Solara announces closure of US FDA inspection at Puducherry facility

The Puducherry facility, dedicated to Ibuprofen and its derivatives, is equipped with advanced infrastructure to serve both domestic and international markets

Solara’s Mangalore facility clears FDA inspection with VAI status

Sandeep Rao appointed MD and CEO of Solar Active Pharma Sciences

Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025

USFDA concludes inspection at Solara's Cuddalore facility with Zero 483 inspectional observations

Green chemistry approaches to synthesis could make a big difference to pharma product outputs

Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies

Green ChemisTree Foundation announces virtual conference on Innovations in Green & Sustainable Chemistry for Pharma Industry

Aim of the virtual conference is to facilitate Indian Pharma Industry adopt Green & Sustainable Chemistry as a tool to enhance Economic & Environmental Competitiveness

Solara announces restoration of CEP for ranitidine hydrochloride

Ranitidine Hydrochloride is an important product for Solara and is manufactured at its Cuddalore site

Aurore to merge with Solara in an all-stock transaction

The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions